Gyre Therapeutics (GYRE) Other Non-Current Assets (2011 - 2026)
Gyre Therapeutics (GYRE) reported Other Non-Current Assets of $4.9 million for Q1 2026, down 11.05% year-over-year from $5.6 million in Q1 2025, and down 2.1% on a QoQ basis from $5.0 million in Q4 2025.
Gyre Therapeutics (GYRE) has 16 years of Other Non-Current Assets data on file, last reported at $4.9 million in Q1 2026.
- Quarterly Other Non-Current Assets fell 11.05% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (down 11.05% YoY) and the FY2025 annual result came in at $5.0 million, up 66.6% from the prior year.
- Other Non-Current Assets retreated to $4.9 million in Q1 2026 per GYRE's latest filing, from $5.0 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $5.6 million in Q1 2025 and bottomed at $168000.0 in Q2 2022.
- The 5-year median for Other Non-Current Assets is $1.3 million (2024), against an average of $2.3 million.
- The widest annual swing landed in 2022, when Other Non-Current Assets tumbled 85.63%; it then soared 1546.43% in 2024.
- Tracing GYRE's Other Non-Current Assets over 5 years: stood at $3.4 million in 2022, then plunged by 70.68% to $995000.0 in 2023, then soared by 204.52% to $3.0 million in 2024, then soared by 66.6% to $5.0 million in 2025, then declined by 2.1% to $4.9 million in 2026.
- Per Business Quant, the three latest GYRE Other Non-Current Assets figures stand at $4.9 million (Q1 2026), $5.0 million (Q4 2025), and $5.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | 4.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.94 Mn |
| Dec 31, 2025 | 5.05 Mn |
| Sep 30, 2025 | 5.32 Mn |
| Jun 30, 2025 | 5.34 Mn |
| Mar 31, 2025 | 5.56 Mn |
| Dec 31, 2024 | 3.03 Mn |
| Sep 30, 2024 | 2.77 Mn |
| Jun 30, 2024 | 1.28 Mn |
| Mar 31, 2024 | 802,000.00 |
| Dec 31, 2023 | 995,000.00 |
| Sep 30, 2023 | 168,000.00 |
| Jun 30, 2023 | 168,000.00 |
| Mar 31, 2023 | 168,000.00 |
| Dec 31, 2022 | 3.39 Mn |
| Sep 30, 2022 | 168,000.00 |
| Jun 30, 2022 | 168,000.00 |
| Mar 31, 2022 | 472,000.00 |
| Dec 31, 2021 | 472,000.00 |
| Sep 30, 2021 | 869,000.00 |
| Jun 30, 2021 | 1.17 Mn |
| Mar 31, 2021 | 528,000.00 |
| Dec 31, 2020 | 528,000.00 |
| Sep 30, 2020 | 698,000.00 |
| Jun 30, 2020 | 198,000.00 |
| Mar 31, 2020 | 197,000.00 |
| Dec 31, 2019 | 257,000.00 |
| Sep 30, 2019 | 257,000.00 |
| Jun 30, 2019 | 257,000.00 |
| Mar 31, 2019 | 197,000.00 |
| Dec 31, 2018 | 543,000.00 |
| Sep 30, 2018 | 352,000.00 |
| Jun 30, 2018 | 274,000.00 |
| Mar 31, 2018 | 128,000.00 |
| Dec 31, 2017 | 128,000.00 |
| Sep 30, 2017 | 5.50 Mn |
| Jun 30, 2017 | 100,000.00 |
| Mar 31, 2017 | 125,000.00 |
| Dec 31, 2016 | 125,000.00 |
| Sep 30, 2016 | 125,000.00 |
| Jun 30, 2016 | 125,000.00 |
| Mar 31, 2016 | 125,000.00 |
| Dec 31, 2015 | 125,000.00 |
| Sep 30, 2015 | 125,000.00 |
| Jun 30, 2015 | 6,000.00 |
| Mar 31, 2015 | 9,000.00 |
| Dec 31, 2014 | 12,000.00 |
| Sep 30, 2014 | 19,000.00 |
| Jun 30, 2014 | 18,000.00 |
| Mar 31, 2014 | 27,000.00 |
| Dec 31, 2013 | 40,000.00 |
| Sep 30, 2013 | 52,000.00 |
| Jun 30, 2013 | 105,000.00 |
| Mar 31, 2013 | 287,000.00 |
| Dec 31, 2012 | 116,000.00 |
| Dec 31, 2011 | 476,000.00 |